Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: Results from a cross-sectional study

Journal of Sexual Medicine

Volumn 11, Issue 8, 2014, Pages 2074-2082

  Russo, Giorgio Ivan ^a   Cimino, Sebastiano ^a   Fragalà, Eugenia ^a   Privitera, Salvatore ^a   La Vignera, Sandro ^a   Condorelli, Rosita ^a   Calogero, Aldo E ^a   Castelli, Tommaso ^a   Favilla, Vincenzo ^a   Morgia, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Erectile dysfunction; HOMA; Insulin resistance; IPSS; LUTS; Metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MIDDLE AGED; PENIS ERECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ERECTILE DYSFUNCTION; HOMA; INSULIN RESISTANCE; IPSS; LUTS; METABOLIC SYNDROME;

AGED; COITUS; CROSS-SECTIONAL STUDIES; ERECTILE DYSFUNCTION; HUMANS; INSULIN RESISTANCE; LOWER URINARY TRACT SYMPTOMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; ORGASM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RISK FACTORS; TESTOSTERONE; URINATION;

EID: 84905014893     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12587     Document Type: Article

References (37)

1. Lee YC, Huang SP, Liu CC, Yang YH, Yeh HC, Li WM, Wu WJ, Wang CJ, Juan YS, Huang CN, Hour TC, Chang CF, Huang CH. The association of eNOS G894T polymorphism with metabolic syndrome and erectile dysfunction. J Sex Med 2012;9:837-843.
2. Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: Analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med 2013;10:2044-2052.
3. Weinberg AE, Eisenberg M, Patel CJ, Chertow GM, Leppert JT. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. J Sex Med 2013;10:3102-3109.
4. Morgia G, Cimino S, Favilla V, Russo GI, Squadrito F, Mucciardi G, Masieri L, Minutoli L, Grosso G, Castelli T. Effects of Serenoa repens, selenium and lycopene (Profluss(R)) on chronic inflammation associated with benign prostatic hyperplasia: Results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. Int Braz J Urol 2013;39:214-221.
5. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-825.
6. Brookes ST, Link CL, Donovan JL, McKinlay JB. Relationship between lower urinary tract symptoms and erectile dysfunction: Results from the Boston Area Community Health Survey. J Urol 2008;179:250-255, discussion 55.
7. Favilla V, Cimino S, Salamone E, Fragalà E, Madonia M, Condorelli R, La Vignera S, Mongioì L, Pirozzi Farina F, Russo GI, Morgia G. Risk factors of sexual dysfunction after transurethral resection of the prostate (TURP): A 12 months follow-up. J Endocrinol Invest 2013;36:1094-1098.
8. Fusco F, D'Anzeo G, Sessa A, Pace G, Rossi A, Capece M, d'Emmanuele di Villa Bianca R. BPH/LUTS and ED: Common pharmacological pathways for a common treatment. J Sex Med 2013;10:2382-2393.
9. Yao F, Liu L, Zhang Y, Huang Y, Liu D, Lin H, Liu Y, Fan R, Li C, Deng C. Erectile dysfunction may be the first clinical sign of insulin resistance and endothelial dysfunction in young men. Clin Res Cardiol 2013;102:645-651.
10. Francavilla S, Properzi G, Bellini C, Marino G, Ferri C, Santucci A. Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction. J Urol 1997;158:1770-1774.
11. Morano S. Pathophysiology of diabetic sexual dysfunction. J Endocrinol Invest 2003;26:65-69.
12. Favilla V, Russo GI, Privitera S, Castelli T, Madonia M, La Vignera S, Condorelli R, Calogero AE, Farina FP, Cimino S, Morgia G. Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: A prospective, randomised controlled study. Andrologia 2013; doi: 10.1111/and.12178.
13. Sebastiano C, Vincenzo F, Tommaso C, Giuseppe S, Marco R, Ivana C, Giorgio R, Massimo M, Giuseppe M. Dietary patterns and prostatic diseases. Front Biosci (Elite Ed) 2012;4:195-204.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
15. Barry MJ, Fowler FJ, Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-1557, discussion 64.
16. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-351.
17. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562-2568.
18. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: Linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010;70:79-89.
19. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-203, discussion 04-6.
20. Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, Kim YJ, Lee JH. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013;82:674-679.
21. Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: A new metabolic disease? J Endocrinol Invest 2014; doi: 10.1007/s40618-014-0051-3.
22. Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M. Metabolic syndrome and lower urinary tract symptoms: The role of inflammation. Prostate Cancer Prostatic Dis 2013;16:101-106.
23. Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, Filippi S, Logiodice F, Carini M, Nesi G, Gacci M, Piccinni MP, Adorini L, Maggi M. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012;214:31-43.
24. Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M. PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013;73:1391-1402.
25. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, Piccinni MP, Saad F, Adorini L, Vannelli GB, Maggi M. Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit. J Endocrinol 2012;212:71-84.
26. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol 2012;132:80-92.
27. Wallner LP, Hollingsworth JM, Dunn RL, Kim C, Herman WH, Sarma AV. Hyperglycemia, hyperinsulinemia, insulin resistance, and the risk of BPH/LUTS severity and progression over time in community dwelling black men: The Flint Men's Health Study. Urology 2013;82:881-886.
28. Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: The Osteoporotic Fractures in Men study. Eur Urol 2011;60:1173-1180.
29. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-718.
30. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: The road map to cardiovascular diseases. Diabetes Metab Res Rev 2006;22:423-436.
31. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: A pathway to cardiovascular disease. Diabetologia 2008;51:527-539.
32. Karthikeyan VJ, Blann AD, Baghdadi S, Lane DA, Gareth Beevers D, Lip GY. Endothelial dysfunction in hypertension in pregnancy: Associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. Clin Res Cardiol 2011;100:531-537.
33. Knoblovits P, Costanzo PR, Valzacchi GJ, Gueglio G, Layus AO, Kozak AE, Balzaretti MI, Litwak LE. Erectile dysfunction, obesity, insulin resistance, and their relationship with testosterone levels in eugonadal patients in an andrology clinic setting. J Androl 2010;31:263-270.
34. Vignozzi L, Filippi S, Comeglio P, Cellai I, Sarchielli E, Morelli A, Rastrelli G, Maneschi E, Galli A, Vannelli GB, Saad F, Mannucci E, Adorini L, Maggi M. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit. Mol Cell Endocrinol 2014;384:143-154.
35. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002;87:4522-4527.
36. Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Despres JP, Bouchard C. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: The HERITAGE Family Study. J Clin Endocrinol Metab 2000;85:1026-1031.
37. Lotti F, Corona G, Vignozzi L, Rossi M, Maseroli E, Cipriani S, Gacci M, Forti G, Maggi M. Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J Androl 2014; doi: 10.4103/1008-682X.126386.